Skip to main content

Advertisement

SpringerLink
Log in

Aberrant microRNA expression in tumor mycosis fungoides

  • Original Article
  • Published:
Tumor Biology

Abstract

Herein, miRNA candidates relevant to mycosis fungoides were investigated to provide data on the molecular mechanisms underlying the pathogenesis of the disease. The miRNA expression profile of skin biopsies from patients with tumor stage MF (tMF) and normal donors was compared using miRNA microarrays. Overall, 154 miRNAs were found differentially expressed between tMF and the control cohort with the majority of them being up-regulated (57 %). Among the upregulated miRNAs, miR-3177, miR-514b-3p, miR-1267, and miR-1282 were exclusively detected in 70 % of tMF. Additional upregulated miRNAs included miR-34a, miR-29a, let-7a*, and miR-210, while miR-200c* was identified among the downregulated ones. Quantitative real-time polymerase chain reaction was used to further investigate the expression profiles of miR-34a and miR-29a and validated the overexpression of miR-34a. Enrichment studies revealed that the target genes of the differentially expressed miRNAs were important in several cancer-related signaling pathways. The overlapping relationship of the target genes among tMF, Sezary syndrome, and atopic dermatitis revealed several common and disease-specific genes. Collectively, our study modulated miR-34a as a candidate oncogenic molecule and miR-29a as a putative tumor suppressor highlighting their promising potential in the molecular pathogenesis of tMF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of cancer (EORTC. Blood. 2007;110(6):1713–22. doi:10.1182/blood-2007-03-055749.

    Article  CAS  PubMed  Google Scholar 

  2. Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288–98.

    Article  PubMed  Google Scholar 

  3. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–73. doi:10.1200/JCO.2015.61.7142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Braoudaki M, Lambrou GI, Giannikou K, Papadodima SA, Lykoudi A, Stefanaki K, et al. miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas. Tumour Biol. 2016. doi:10.1007/s13277-016-4903-7.

    Google Scholar 

  5. Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK, et al. Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol. 2014;7:96. doi:10.1186/s13045-014-0096-y.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Braoudaki M, Lambrou GI. MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol. 2015;8:6. doi:10.1186/s13045-014-0101-5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol. 2011;5(3):273–80. doi:10.1016/j.molonc.2011.02.003.

    Article  PubMed  Google Scholar 

  8. Sandoval J, Diaz-Lagares A, Salgado R, Servitje O, Climent F, Ortiz-Romero PL, et al. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. J Invest Dermatol. 2015;135(4):1128–37. doi:10.1038/jid.2014.487.

    Article  CAS  PubMed  Google Scholar 

  9. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40(Web Server issue):W498–504. doi:10.1093/nar/gks494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41(Web Server issue):W169–73. doi:10.1093/nar/gkt393.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77–83. doi:10.1093/nar/gkt439.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Marosvari D, Teglasi V, Csala I, Marschalko M, Bodor C, Timar B, et al. Altered microRNA expression in folliculotropic and transformed mycosis fungoides. Pathol Oncol Res. 2015;21(3):821–5. doi:10.1007/s12253-015-9897-8.

    Article  CAS  PubMed  Google Scholar 

  13. Gallardo F, Sandoval J, Diaz-Lagares A, Garcia R, D’Altri T, Gonzalez J, et al. Notch1 pathway activation results from the epigenetic abrogation of notch-related MicroRNAs in mycosis fungoides. J Invest Dermatol. 2015;135(12):3144–52. doi:10.1038/jid.2015.328.

    Article  CAS  PubMed  Google Scholar 

  14. Maj J, Jankowska-Konsur A, Sadakierska-Chudy A, Noga L, Reich A. Altered microRNA expression in mycosis fungoides. Br J Dermatol. 2012;166(2):331–6. doi:10.1111/j.1365-2133.2011.10669.x.

    Article  CAS  PubMed  Google Scholar 

  15. McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(4):1101–7. doi:10.1038/jid.2013.461.

    Article  CAS  PubMed  Google Scholar 

  16. Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116(7):1105–13. doi:10.1182/blood-2009-12-256719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014;34(12):7207–17.

    CAS  PubMed  Google Scholar 

  18. Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27(3):443–52. doi:10.1016/j.cellsig.2014.12.003.

    Article  CAS  PubMed  Google Scholar 

  19. Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, et al. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia. 2014;28(2):451–5. doi:10.1038/leu.2013.298.

    Article  CAS  PubMed  Google Scholar 

  20. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963–70. doi:10.3892/mmr_00000199.

    CAS  PubMed  Google Scholar 

  21. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009;124(3):568–77. doi:10.1002/ijc.23948.

    Article  CAS  PubMed  Google Scholar 

  22. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011;6(10):e25114. doi:10.1371/journal.pone.0025114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ruiz Esparza-Garrido R, Velazquez-Flores MA, Diegoperez-Ramirez J, Lopez-Aguilar E, Siordia-Reyes G, Hernandez-Ortiz M, et al. A proteomic approach of pediatric astrocytomas: MiRNAs and network insight. J Proteome. 2013;94:162–75. doi:10.1016/j.jprot.2013.09.009.

    Article  CAS  Google Scholar 

  24. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene. 2011;30(22):2587–94. doi:10.1038/onc.2010.634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rizzo M, Mariani L, Cavallini S, Simili M, Rainaldi G. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation. Nucleic Acid Ther. 2012;22(4):283–8. doi:10.1089/nat.2012.0343.

    CAS  PubMed  Google Scholar 

  26. Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol. 2010;130(4):1126–35. doi:10.1038/jid.2009.306.

    Article  CAS  PubMed  Google Scholar 

  27. Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, et al. miR-29 s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015;6(15):12837–61. doi:10.18632/oncotarget.3805.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yan B, Guo Q, FJ F, Wang Z, Yin Z, Wei YB, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539–48. doi:10.2147/OTT.S75899.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C, et al. Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014;3:17. doi:10.1186/2162-3619-3-17.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Di Lisio L, Sanchez-Beato M, Gomez-Lopez G, Rodriguez ME, Montes-Moreno S, Mollejo M, et al. MicroRNA signatures in B-cell lymphomas. Blood. Cancer J. 2012;2(2):e57. doi:10.1038/bcj.2012.1.

    CAS  Google Scholar 

  31. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia. 2007;21(12):2547–9. doi:10.1038/sj.leu.2404853.

    Article  CAS  PubMed  Google Scholar 

  32. Huang HB, Zhan R, SQ W, ZZ X, Fan LP. Expression of MCL-1 and microRNA-29a in extranodal NK/T-cell lymphoma tissue. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(1):95–8. doi:10.7534/j.issn.1009-2137.2013.01.020.

    CAS  PubMed  Google Scholar 

  33. Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE, et al. Involvement of MicroRNA in T-cell differentiation and malignancy. Int J Hematol Oncol Stem Cell Res. 2015;9(1):33–49.

    PubMed  PubMed Central  Google Scholar 

  34. Zhu Y, Xu A, Li J, Fu J, Wang G, Yang Y, et al. Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer. Cancer Biomark. 2016;16(2):259–64. doi:10.3233/CBM-150563.

    Article  CAS  PubMed  Google Scholar 

  35. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19–36. doi:10.1677/ERC-09-0184.

    Article  CAS  PubMed  Google Scholar 

  36. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015;16(3):6353–72. doi:10.3390/ijms16036353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Qin Q, Furong W, Baosheng L. Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 2014;33:50. doi:10.1186/1756-9966-33-50.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zhao M, Wang LT, Liang GP, Zhang P, Deng XJ, Tang Q, et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol. 2014;150(1):22–30. doi:10.1016/j.clim.2013.10.009.

    Article  CAS  PubMed  Google Scholar 

  39. Kamstrup MR, Ralfkiaer E, Skovgaard GL, Gniadecki R. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2008;158(4):747–53. doi:10.1111/j.1365-2133.2007.08427.x.

    Article  CAS  PubMed  Google Scholar 

  40. Kamstrup MR, Gjerdrum LM, Biskup E, Lauenborg BT, Ralfkiaer E, Woetmann A, et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2010;116(14):2504–12. doi:10.1182/blood-2009-12-260216.

    Article  CAS  PubMed  Google Scholar 

  41. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252–63. doi:10.1038/nrm2868.

    Article  CAS  PubMed  Google Scholar 

  42. Masliah-Planchon J, Garinet S, Pasmant E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2015. doi:10.18632/oncotarget.6476.

    Google Scholar 

  43. Liao JM, Cao B, Zhou X, Lu H. New insights into p53 functions through its target microRNAs. J Mol Cell Biol. 2014;6(3):206–13. doi:10.1093/jmcb/mju018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sivadas VP, Kannan S. The microRNA networks of TGFbeta signaling in cancer. Tumour Biol. 2014;35(4):2857–69. doi:10.1007/s13277-013-1481-9.

    Article  CAS  PubMed  Google Scholar 

  45. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886–96. doi:10.1200/JCO.2005.11.353.

    Article  PubMed  Google Scholar 

  46. Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, Vergier B, Jouary T, Beylot-Barry M, et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 2010;130(3):816–25. doi:10.1038/jid.2009.314.

    Article  CAS  PubMed  Google Scholar 

  47. Karenko L, Hahtola S, Paivinen S, Karhu R, Syrja S, Kahkonen M, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res. 2005;65(18):8101–10. doi:10.1158/0008-5472.CAN-04-0366.

    Article  CAS  PubMed  Google Scholar 

  48. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665–7. doi:10.1111/j.1365-2133.2010.10108.x.

    CAS  PubMed  Google Scholar 

  49. Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Geraud C. Sezary syndrome: old enigmas, new targets. J Dtsch Dermatol Ges. 2016;14(3):256–64. doi:10.1111/ddg.12900.

    PubMed  Google Scholar 

  50. Nagy G, Gaspar K, Irinyi B, Gal M, Tumpek J, Gyimesi E, et al. Association between serum IL-16 levels and the degree of sensitization in patients with atopic dermatitis. Int Arch Allergy Immunol. 2011;156(1):69–74. doi:10.1159/000321959.

    Article  CAS  PubMed  Google Scholar 

  51. Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, et al. Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol. 2011;31(1):39–50. doi:10.1007/s10875-010-9464-8.

    Article  CAS  PubMed  Google Scholar 

  52. Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. Int J Immunopathol Pharmacol. 2011;24(1):15–23.

    CAS  PubMed  Google Scholar 

  53. Lee J, Noh G, Lee S, Youn Y, Rhim J. Atopic dermatitis and cytokines: recent patents in immunoregulatory and therapeutic implications of cytokines in atopic dermatitis--part I: cytokines in atopic dermatitis. Recent Patents Inflamm Allergy Drug Discov. 2012;6(3):222–47.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Dermatology and Cutaneous Lymphoma Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece

    E. Papadavid, V. Nikolaou, A. Ekonomidi & C. Antoniou

  2. 2nd Departments of Dermatology and Cutaneous Lymphoma clinic, Attikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece

    E. Papadavid & D. Rigopoulos

  3. University Research Institute for the Study and Treatment of Childhood Genetic and Malignant Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece

    M. Braoudaki

  4. Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece

    M. Braoudaki, A. Lykoudi, G. Tounta, S. Kitsiou-Tzeli & A. Kolialexi

  5. Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Soranou Ephessiou 4, 115 27, Athens, Greece

    M. Bourdakou, E. Athanasiadis & G. Spyrou

Authors
  1. E. Papadavid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Braoudaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bourdakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Lykoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Nikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Tounta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ekonomidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Athanasiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Spyrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Antoniou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Kitsiou-Tzeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Rigopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Kolialexi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Kolialexi.

Ethics declarations

Conflicts of interest

None

Authors’ contributions

EP conceived and designed the study, performed patients’ diagnosis and treatment, and drafted the manuscript. MBr performed all experiments, participated in the interpretation of data analyses, and drafted the manuscript. LA and TG assisted in all experiments’ performance. MB, EA, and GS performed bioinformatics analyses. VN and CA performed tumor diagnosis and treated patients. SKT, DR, and AK participated in the coordination of the study. AK also participated in study design and supervised the study. All authors approved the final manuscript.

Additional information

E Papadavid and M Braoudaki contributed equally to this work.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papadavid, E., Braoudaki, M., Bourdakou, M. et al. Aberrant microRNA expression in tumor mycosis fungoides. Tumor Biol. 37, 14667–14675 (2016). https://doi.org/10.1007/s13277-016-5325-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5325-2

Keywords

Search

Navigation